Acute Care Therapeutics for Surgical Settings

Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

About Baudax Bio

We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including one candidate in later stage regulatory review with FDA.

About Us

Our Innovative Pipeline

Our product pipeline contains valuable therapeutic product candidate options for patients and healthcare providers in acute care settings.

Product Pipeline

Latest News

Baudax Bio Announces Closing of $25 Million Public Offering of Securities

View Press Release

Baudax Bio Announces Closing of $25 Million Public Offering of Securities

View Press Release

Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants

View Press Release

Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants

View Press Release

Baudax Bio Signs Non-Binding Term Sheet for Debt Facility

View Press Release

Baudax Bio Announces FDA Approval of ANJESO™ for the Management of Moderate to Severe Pain

View Press Release

Baudax Bio Reports 2019 Annual Financial Results

View Press Release

Baudax Bio Announces PDUFA Date for Intravenous Meloxicam

View Press Release

Baudax Bio to Present at the Piper Jaffray 31st Annual Healthcare Conference

View Press Release

Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies

View Press Release

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today